Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome.
Light, Kathleen C, Agarwal, Neeraj, Iacob, Eli et al. · Psychoneuroendocrinology · 2013 · DOI
Quick Summary
This study compared how certain genes are turned 'on' and 'off' differently in blood cells from people with ME/CFS, men with prostate cancer receiving hormone therapy, and healthy people. The researchers found that while both patient groups experience severe fatigue, they show different patterns of gene activity, suggesting that fatigue in these conditions may arise from different biological mechanisms. One gene related to calming the nervous system (DBI) was linked to fatigue severity in both patient groups, offering a potential target for future treatments.
Why It Matters
Understanding that ME/CFS and similar fatigue states involve distinct genetic expression patterns could explain why treatments effective for one condition may not work for another. Identifying genes like DBI and P2RY1 as correlates of fatigue severity provides biological leads for developing targeted interventions. This work bridges immunology, metabolic dysfunction, and neuroendocrine pathways in ME/CFS pathogenesis.
Observed Findings
Prostate cancer patients showed higher expression of NR3C1, TLR4, CXCR4, and SOD2 but lower expression of ADRB2, VIPR2, TNF, LTA, ASIC3, and P2RX7 compared to ME/CFS patients and controls.
ME/CFS patients showed higher P2RX7 and lower HSPA2 expression compared to both prostate cancer patients and controls.
DBI (GABA-A receptor modulator) expression correlated negatively with fatigue severity in both patient groups (r = −0.50 for prostate cancer, r = −0.34 for ME/CFS).
P2RY1 (purinergic receptor) correlated positively only with prostate cancer fatigue and pain severity (r = +0.43 and +0.59).
Prostate cancer patients differed from controls and ME/CFS patients in mean expression of 10 genes spanning all five biological pathways.
Inferred Conclusions
Fatigue in prostate cancer and ME/CFS arises from distinct biological pathways, despite symptomatic similarity.
DBI may represent a shared molecular correlate of fatigue across different disease contexts.
Purinergic signaling (P2RX7, P2RY1) may be particularly relevant to ME/CFS pathophysiology.
These gene expression patterns offer potential therapeutic targets for fatigue reduction in both conditions.
Remaining Questions
Do the observed gene expression differences cause fatigue, or are they consequences of illness-related stress and immune activation?
What This Study Does Not Prove
This study does not prove that gene expression differences *cause* fatigue—only that they are associated with it. The cross-sectional design means causality cannot be determined, and correlation does not establish mechanism. The study also does not address whether gene expression changes are primary drivers of ME/CFS or secondary consequences of the illness.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.